Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.2K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.2K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.6K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.6K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

577
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
577
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

524
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
524
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of clinical and imaging predictors of response to corticosteroid therapy in inflammatory dacryoadenitis.

Orbit (Amsterdam, Netherlands)·2026
Same author

Predictors of Cerebral Small-Vessel Disease in Middle-Aged, Virologically Controlled People Living With HIV.

Open forum infectious diseases·2026
Same author

Quantitative CT-scan to evaluate cerebral edema secondary to hyperammonemia in ICU: A proof-of-concept study.

Journal of intensive medicine·2026
Same author

Cladribine use for multiple sclerosis with autoimmune comorbidities: retrospective analysis of the French MS registry, case series, and therapeutic considerations.

Therapeutic advances in neurological disorders·2026
Same author

Re: Dones et al.: Emergency department use of ocular point-of-care ultrasound and its utility in diagnosis at a tertiary academic medical center (Ophthalmology. 2026;133:720-727).

Ophthalmology·2026
Same author

Combination of color-Doppler ultrasound and MRI to improve lacrimal gland lesion characterization: A machine learning approach.

Diagnostic and interventional imaging·2026

Related Experiment Video

Updated: Jul 29, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Natalizumab extended-interval dosing in a real-life setting.

Lina Jeantin1, Marine Boudot de la Motte1, Romain Deschamps1

  • 1Neurology department, Hopital Fondation Adolphe de Rothschild, 25-29 rue Manin, Paris, France.

Journal of the Neurological Sciences
|May 21, 2023
PubMed
Summary

Extending the natalizumab infusion interval from four to six weeks in patients with relapsing multiple sclerosis (RMS) demonstrated comparable safety and efficacy. This change did not increase relapse rates or MRI activity in a real-world setting.

Keywords:
Immunosuppressive agentsMagnetic resonance imagingMultiple sclerosisNatalizumabRecurrence

More Related Videos

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
07:59

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response

Published on: May 31, 2024

1.5K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K

Related Experiment Videos

Last Updated: Jul 29, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
07:59

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response

Published on: May 31, 2024

1.5K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Natalizumab is an effective treatment for relapsing multiple sclerosis (RMS).
  • Current treatment involves a four-week administration interval.
  • Previous studies suggest extending the interval to six weeks may improve safety without compromising efficacy.

Purpose of the Study:

  • To evaluate the safety and efficacy of extending the natalizumab dosing interval from four to six weeks in a real-world setting for RMS patients.

Main Methods:

  • A monocentric retrospective self-controlled study was conducted.
  • Adult RMS patients on a four-week natalizumab interval for at least six months were switched to a six-week interval.
  • Outcomes included MS relapse incidence, new MRI lesions, and MRI activity signs, comparing the two dosing periods within the same patients.

Main Results:

  • Fifty-seven patients were analyzed.
  • No MS relapses occurred during either the four-week or six-week interval periods.
  • New MRI lesions were observed in 13.5% of patients during the four-week interval and 3.6% during the six-week interval.

Conclusions:

  • Extending the natalizumab dosing interval to six weeks is safe and effective for RMS patients.
  • No increase in relapses or MRI activity was observed with the extended interval.
  • This real-world data supports the potential for longer interdose intervals in managing RMS.